QIBA FDG-PET/CT Tech Ctte Update Call

March 30, 2012 at 9 am CT Call Summary

RSNA

Julie Lisiecki

In attendance:Constantine Gatsonis, PhDScott D. Wollenweber, PhDPaul Kinahan, PhD (co-chair)Howard Higley, PhDJohn Wolodzko, PhD

Richard Wahl, MD (co-chair)Martin Lodge, PhDKeith AllbergLing X. Shao, PhDAndrew Buckler, MSAnne M. Smith, PhDPaul E. ChristianJohn Sunderland, PhD

Patricia Cole, PhD, MD Valerie Treyer, PhD
Barbara Croft, MD Timothy G. Turkington, PhD

Discussion regarding the Profile updates (Dr. Kinahan)

- Three sections of the Profile requiring additional clarification were discussed:
 - Summary for Clinical Trial Use
 - Clinical Context and Claims Utilities and Endpoints for Clinical Trials
 - Profile Details
- Acronyms and definitions were included in the preamble
- Two colors have been used in the tables
 - White: to indicate normative requirements and
 - Shaded grey: to show ideal informative information
- Clarification of terms suggested:
 - 'Parameter' instead of 'category'
 - o Terms in the abbreviations section: SUV, SUVmax, etc.
 - o Add reference for "most malignant tumors" and hyperlink to CMS site
- Add references and analysis as an appendix
- Focus of Profile audience discussed: clinical trials only vs. clinical trials and clinical therapy
 - Agreed that the Profile can focus on both with the caveat that validation for clinical trials may have different requirements
- Current protocol is 83 pages need to make sure all normative items are covered

Next steps:

- Dr. Kinahan to incorporate edits from 3/30 call and circulate to the group for review prior to the next call
- Continue discussion of final Profile edits on next call prior to release for Public Comment
- Dr. Kinahan to add references and analysis as an appendix
- Dr. Kinahan to clarify some of the terms in the abbreviations section: SUV, SUVmax, etc.
- Drs. Kinahan, Gatsonis, Lodge, Higley and Mr. Buckler to have an offline call to clarify statistics/ metanalysis
- Final draft of NIBIB application needed by early April

Next call: to continue discussion of the Profile at 9 am (CT), April 13th